One-Way Intestinal Perfusion of PVP/VA–Poloxamer ...

鄭重說明:

您值得信賴的中藥成分及標(biāo)準(zhǔn)合作伙伴滿足您研發(fā)和工業(yè)化需求

產(chǎn)品關(guān)鍵詞：香草酸-4-β-D-葡萄糖苷 6-甲氧基山奈酚茯苓新酸B 去甲異波爾定

guanyuwomen關(guān)于德思特

聯(lián)系方式

服務(wù)熱線：

028-8500-3950

公司傳真：	028-85589956
公司郵箱：	sales@tcmlmt.com
公司網(wǎng)址：	www.chuaihan.com
公司地址：	四川省成都市溫江區(qū)?？坡肺鞫?28號(hào)5棟

發(fā)表文獻(xiàn)展示

當(dāng)前位置:首頁關(guān)于德思特 > 發(fā)表文獻(xiàn)展示 >

時(shí)間：2022-05-30 瀏覽次數(shù)：分享到：

Turmeric was the dried rhizome of Curcuma longa L., and its extract had important pharmacological effects such as anti-tumor, cholagogic, and antioxidant. However,curcuma extract had poor water solubility and low bioavailability, which had become the main limiting factor for its clinical application. The purpose of this study was to prepare PVP/VA–Poloxamer–188–curcuma extract solid dispersion (PAP–CSD) to improve the solubilityand bioavailability of the curcuma extract. The intestinal absorption mechanism of solid dispersion of this extract was studied by one-way intestinal perfusion in rats. PAP–CSD,PVP/VA–curcuma extract solid dispersion (PA–CSD) and Poloxamer–188–curcuma extract solid dispersion (P–CSD) was able to improve the intestinal absorption of the curcuma extract (P< 0.05), and PAP–CSD (combined use of two carriers) was better than that of PA–CSD and P–CSD. CCK8 method was used to investigate the effects of the curcuma extract and PAP–CSD on the proliferation of hepatic stellate cells (HSC)–T6 cells. The inhibitory effect ofPAP–CSD on the proliferation of HSC-T6 cells, related to the p38 MAPK pathway, was better than that of the curcuma extract.

...

Materials

Bisdemethoxycurcumin reference substance, demethoxycurcumin reference substance, and curcumin reference substance were all purchased from Chengdu DST Biotechnology Co., Ltd. (batch number: DST191009-021, DST190910-030, DST200412-014),

...

上一篇：Astilbin ameliorates depressive-like behavior caused ...

下一篇：最后一頁

Afrormosine CAS:550-79-8 中藥對(duì)照品標(biāo)準(zhǔn)品

產(chǎn)品編碼：DA0040產(chǎn)品名稱：Afrormosine英文名:AfrormosineCAS登錄...